slides · global inventory
Problem Agitate Solution
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 26,550
Current window 21,781-21,810
Pages 885
Rows per page 30
Arc
21,781-21,810 of 26,550
56
Includes two distinct chart types: a scatter plot for half-life correlation and bar charts for ADA rates.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
08
The slide uses a process-oriented flow diagram to explain the mechanism of action for a combination therapy.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
09
The slide highlights the mechanism of action targeting multiple HBV transcripts.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
10
The slide outlines study design for Part 1, 2, and 3 of a clinical trial for chronic hepatitis B (cHBV).Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
11
Data presented at Global Hepatitis Summit 2023. Includes specific cohort N values and standard error (SE) in parentheses.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
12
The slide displays six longitudinal line charts representing different patient cohorts, with specific callouts for clinical outcomes.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
13
Clinical trial data showing individual patient responses over time.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
03
The slide uses a list-based layout to present three key clinical findings.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
04
The slide uses a high-level mission statement as the primary anchor for the presentation.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
05
The slide uses a central portrait of a patient (Crystal) to humanize the clinical data points surrounding her.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
07
The slide uses a process flow diagram to illustrate the patient journey through the trial, including specific durations and transition criteria.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
08
The table displays mean (SD) or n (%) for various clinical metrics including age, gender, diagnosis duration, and disease activity scores.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
09
The slide highlights efficacy across different patient subsets and mentions specific clinical metrics (INCAT, I-RODS, grip strength).argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
10
The slide uses a Kaplan-Meier plot to demonstrate clinical efficacy.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
11
The table includes hazard ratios, p-values, and mean changes from baseline for CIDP disease progression and functional scores.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
12
The slide presents clinical trial safety data for VYVGART Hytrulo.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
13
Uses a 'before-after' framing to contrast legacy treatments (IVIg, Steroids, PLEX) with the new product's benefits.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
14
The slide uses a bubble-based layout to showcase brand logos and study names centered around the corporate brand.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
16
The slide uses a hub-and-spoke circular diagram to represent organizational values.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Action1 hit
05
The slide uses a high-contrast blue box to highlight the core product value proposition.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
06
Highlights the repurposing of the active ingredient in Viagra for a new indication with no current FDA-approved treatments.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
07
Dare Bioscience | Investor Presentation Deck | 27 slidesDare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
08
The slide uses a comparison framework to contrast existing treatments for other conditions with the lack of treatments for FSAD.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
09
This slide outlines regulatory requirements for clinical trial design, including placebo run-in periods, patient population definition, PRO instruments, and primary endpoints.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
10
Dare Bioscience | Investor Presentation Deck | 27 slidesDare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
11
Includes a visual comparison indicating FSAD is not equal to HSDD.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
12
Uses medical diagnostic criteria (DSM) to frame the business opportunity by analogy.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
13
The slide uses a bulleted list structure to categorize the patient experience into physical symptoms, motivations, emotional impact, and psychological concerns.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
14
Includes a highlighted section emphasizing the 10 million women actively seeking treatment.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
15
Dare Bioscience | Investor Presentation Deck | 27 slidesDare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit